본문 바로가기

바이오스펙테이터

기사본문

pH Pharma, positive P2b results for drug candidate for normal tension glaucoma treatment at the APAO 2019

입력 2019-03-22 12:17 수정 2019-12-20 09:05

바이오스펙테이터 Sungmin Kim 기자

이 기사는 '프리미엄 뉴스서비스 BioS+' 기사입니다.
PHP-201 demonstrated superiority to placebo for the effect of lowering intraocular pressure (IOP) in patients with normal tension glaucoma

pH Pharma Co., Ltd. presented positive results of phase 2 clinical study of PHP-201, a new drug candidate for treatment of glaucoma, at the 2019 Asia-Pacific Academy of Ophthalmology (APAO 2019) on March 9th in Bangkok, Thailand.

The phase 2 clinical trial entitled “Double-masked, Randomized, Dose-Response of Phase 2 Study of PHP-201 in patients with Normal Tension Glaucoma” was presented by Dr. Ki Ho Park, chairman of ophthalmology at Seoul National University and principal investigator of the trial. Dr. Park was awarded Best Scientific Paper Award at APAO 2019.

"PHP-201 demonstrated superiority to placebo for the effect of lowering intraocular pressure (IOP) in patients with normal tension glaucoma," said Dr. Park. “In addition, the incidence of conjunctival hyperemia was much lower than currently available drugs, and no significant side effects were observed." Conjunctival hyperemia is usually one of the most common side effects of eye drops for glaucoma treatment.

Normal tension glaucoma is a form of glaucoma in which damage occurs to the optic nerve without eye pressure exceeding the normal range. Currently, there are no drugs specifically developed for the treatment of normal tension glaucoma....

'프리미엄 뉴스서비스 BioS+'는 독자들에게 가치(value)있는 기사를 제공합니다.
추가내용은 유료회원만 이용할 수 있습니다.
회원이시면 로그인 해주시고, 회원가입을 원하시면 클릭 해주세요.